Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biocare Private Limited, has entered into a strategic agreement with Orion Corporation, a pharmaceutical company based in Finland. The agreement grants Orion exclusive rights to distribute, market, and sell Shilpa’s Recombinant Human Albumin in the European market.
The product, currently under development, is a biosimilar version of human albumin produced using a non-human expression system. This production approach aims to offer an alternative to plasma-derived albumin by eliminating risks related to human pathogens and improving scalability.
As part of the agreement, Shilpa Biocare is eligible to receive development and regulatory milestone payments from Orion. Shilpa has been investing in the development of Recombinant Human Albumin for approximately eight years and has established a large-scale fermentation facility to support its production.
Recombinant Human Albumin is used in a variety of therapeutic applications and plays a critical role in the manufacturing of vaccines and other biologics. The collaboration is expected to leverage Orion’s experience in the European pharmaceutical market, including its regulatory and distribution capabilities.
The partnership reflects ongoing industry efforts to enhance the availability of biologics and biosimilars that meet safety and quality standards.
Ahmedabad Plane Crash